الانتقال إلى المحتوى الرئيسي
xMedica

NCT06056830ClinicalTrials.gov

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

المرحلة 3مطلوب 383 مشاركاً34 موقعاً3 دول

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2023-09-28; recorded start 2023-12-21
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Clarity Pharmaceuticals Ltd)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 31 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 383 participants (target), run at 34 sites, across 3 countries.

How this score is built
  • Enrolment25/40

    383 participants (target)

  • Site count18/25

    31 sites

  • Country count7/15

    3 countries

  • Planned duration8/10

    Planned over about 33 months

  • Sponsor scale2/10

    Clarity Pharmaceuticals Ltd has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

الحالات

  • Prostate Cancer
  • Prostatic Neoplasms

الأهلية

الأهلية
الجنسذكر
الأعمار18 Yearsلا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * At least 18 years of age. * Signed informed consent. * Untreated, histologically confirmed adenocarcinoma of the prostate. * High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA \>20 ng/mL). * Patients electing to undergo RP with PLND. Exclusion Criteria: * Administration of any high energy (\>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1. * Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components. * Patients with known predominant small cell or neuroendocrine PC.

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 3
التخصيصغير منطبق
نموذج التدخّلSINGLE_GROUP
الغرض الأساسيDIAGNOSTIC
التعميةNONE (0)
التجنيدمطلوب 383 مشاركاً

الجهة الراعية والمتعاونون

  • Clarity Pharmaceuticals Ltd الجهة الراعية

الأذرع والتدخلات

  • 64Cu-SAR-bisPSMAEXPERIMENTAL

    200MBq 64Cu-SAR-bisPSMA.

التدخلات

  • دواء 64Cu-SAR-bisPSMA

    All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases

    Independent primary endpoints for Day 1 and Day 2 PET: Co-primary endpoint of sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer within the pelvic lymph nodes compared to the Standard of Truth.

    الإطار الزمني Up to 16 weeks

  2. مقياس النتيجة الثانوي

    Safety and tolerability of 64Cu-SAR-bisPSMA

    Incidence and severity of treatment-emergent AEs and SAEs following administration of 64Cu-SAR-bisPSMA

    الإطار الزمني Up to 16 weeks

  3. مقياس النتيجة الثانوي

    Consistency of 64Cu-SAR-bisPSMA PET/CT interpretations for the three central readers

    Inter-reader reliability of agreement estimated with a multiple-reader kappa statistic

    الإطار الزمني Up to 16 weeks

  4. مقياس النتيجة الثانوي

    PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs

    PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth

    الإطار الزمني Up to 16 weeks

  5. مقياس النتيجة الثانوي

    Ability of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer

    Sensitivity of 64Cu-SAR-bisPSMA PET to detect PC within the prostate gland compared to the Standard of Truth

    الإطار الزمني Up to 16 weeks

  6. مقياس النتيجة الثانوي

    Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases without subregion matching

    Sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth, without the requirement of subregion (Left or Right) matching between 64Cu-SAR-bisPSMA PET and Standard of Truth

    الإطار الزمني Up to 16 weeks

التواريخ

التواريخ
تاريخ البدء21 ديسمبر 2023 (فعلي)
الإتمام الأولي1 سبتمبر 2026 (تقديري)
الإتمام1 سبتمبر 2026 (تقديري)
أول نشر28 سبتمبر 2023 (فعلي)
آخر تحديث11 سبتمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةسبتمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

34 موقعاً قيد التجنيد

Australia

Australia
المنشأةالمدينةالولاية أو المنطقةالحالة
Fiona Stanley HospitalMurdochWestern Australiaقيد التجنيد
RAMSAY HEALTH CARE AUSTRALIA PTY LIMITED (ABN 36 003 184 889) trading as Hollywood Private HospitalNedlandsWestern Australiaقيد التجنيد
St. Vincent's SydneySydneyNew South Walesقيد التجنيد
Princess Alexandra HospitalWoolloongabbaQueenslandقيد التجنيد

Puerto Rico

Puerto Rico
المنشأةالمدينةالولاية أو المنطقةالحالة
Pan American Center for Oncology Trials, LLC - CiudadelaSan Juanقيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Albany Medical College, Department of UrologyAlbanyNew Yorkقيد التجنيد
Urology Austin, PLLC - Research DepartmentAustinTexasقيد التجنيد
University of Alabama Birmingham HospitalBirminghamAlabamaقيد التجنيد
University of Texas Southwestern Medical CenterDallasTexasقيد التجنيد
Urology Clinics of North TexasDallasTexasقيد التجنيد
Duke University Medical CenterDurhamNorth Carolinaقيد التجنيد
NorthShore University Health System, Glenbrook HospitalGlenviewIllinoisقيد التجنيد
BAMF HealthGrand RapidsMichiganقيد التجنيد
Corewell HealthGrand RapidsMichiganقيد التجنيد
Indiana University School of MedicineIndianapolisIndianaقيد التجنيد
Mayo Clinic- JacksonvilleJacksonvilleFloridaقيد التجنيد
Arkansas Urology Research Center, LLCLittle RockArkansasقيد التجنيد
Greater Los Angeles VA Medical CenterLos AngelesCaliforniaقيد التجنيد
Urology Group of Southern CaliforniaLos AngelesCaliforniaقيد التجنيد
University of WisconsinMadisonWisconsinقيد التجنيد
Biogenix Molecular, LLCMiamiFloridaقيد التجنيد
Intermountain HealthMurrayUtahقيد التجنيد
Carolina Urologic Research CenterMyrtle BeachSouth Carolinaقيد التجنيد
Urology Associates of NashvilleNashvilleTennesseeقيد التجنيد
Mount Sinai Doctors Urology Faculty PracticeNew YorkNew Yorkقيد التجنيد
XCancer Omaha LLCOmahaNebraskaقيد التجنيد
UC Irvine HealthOrangeCaliforniaقيد التجنيد
Mayo Clinic- PhoenixPhoenixArizonaقيد التجنيد
Mayo Clinic- RochesterRochesterMinnesotaقيد التجنيد
The Urology PlaceSan AntonioTexasقيد التجنيد
Oregon UrologySpringfieldOregonقيد التجنيد
Stanford University Medical CenterStanfordCaliforniaقيد التجنيد
Urologic SpecialistsTulsaOklahomaقيد التجنيد
Wichita Urology GroupWichitaKansasقيد التجنيد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 11 سبتمبر 2026

    أُضيف موقع

    3 sites added (34 total)

    3134